Title: Changes in C-Reactive Protein White Blood Cells Counts in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Rosiglitazone
Abstract: Objective To observe the changes in serum C-reactive protein(CRP) and white blood cells(WBC) counts in patients with type 2 diabetes mellitus after treatment with rosiglitazone.Methods A 3-month randomized,double-blind placebo controlled study was performed to compare the effect of placebo and rosiglitazone 4mg/d in 89 type 2 diabetic patients who had received sulfonylureas and metformin treatment.Some markers such as fasting plasma glucose(FPG),2h plasma glucose(2hPG),glycosylated hemoglobin(HbA1c),cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),fast insulin(FIns),C-reactive protein(CRP),white blood cells(WBC) counts were measured before and after treatment.In addition,result of simultaneous examination over 44 healthy volunteers was chosen as contrast.Results A significant reduction in CRP,WBC level was observed after 3-month treatment with rosiglitazone(P0.01).So were FPG,2hPG,HbA1c,TG,and HOMA-IR(P0.05).But there was a significant increase in HDL-C(P0.05).Conclusion The use of rosiglitazone in patients with T2DM can not only improve their glucose,blood-lipid metabolism but also decrease the level of some inflammatory makers,and may have possible good effect to preventing complications of the patients with T2DM.
Publication Year: 2006
Publication Date: 2006-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot